Muharrem Coşkunpınar

Happy to share that I’ve been accepted into the @JCO_ASCO Reviewer Trainee Program 🎉 We had our first meeting today. Peer review is the backbone of scientific publishing. I hope to contribute to this essential process.Many thanks to @ASCO for this opportunity! #JCO #PeerReview

Advancing Precision in Muscle-Invasive Bladder Cancer: The Critical Role of Histologic Subtyping #ASCODailyNews @ASCO #OncSurgery @UTMDAnderson @SagarRPatelMD @TarynAEllis @JosephBBlack dailynews.ascopubs.org/do/advancing-p… #EAU26

🎧 Expert Insights – New Episode Dr. Yüksel Ürün breaks down key Genitourinary oncology studies from ASCO GU26, including: • EV + Pembrolizumab in bladder cancer • Belzutifan combinations in RCC • PARP + ARPI in prostate cancer 🎙️ Watch the full episode: youtu.be/-J4ztmDHYPA #OncologySpotlight #ExpertInsights #CancerCare #OncologyPodcast #MedicalOncology #ONCOassist #Oncoalert #GU26 @DrYukselUrun @ASCO

Staging of Bladder Cancer: CT is accessible and fast for staging. mpMRI with VI-RADS shows higher accuracy for muscle invasion and helps distinguish NMIBC vs MIBC. Where expertise exists, MRI can strengthen bladder preservation strategies. Access and standardization remain key challenges. #gu26 #cancer #oncology #ASCO @oncoalert @ASCO @yekeduz_emre @CParkMD @OncBrothers @Larvol @nataliagandur @crisbergerot @ONCOassist @IMG_Oncologists

Perioperative landscape in MIBC is shifting. @AndreaNecchi Phase 3 trials integrate IO/chemo in neoadjuvant and adjuvant settings. pCR rates with IO combinations, including EV+pembro, are reshaping expectations. Now we need durable survival data. #gu26 #cancer #oncology #ASCO @oncoalert @ASCO @yekeduz_emre @CParkMD @OncBrothers @Larvol @nataliagandur @crisbergerot @ONCOassist @IMG_Oncologists

Response-adapted bladder preservation in MIBC: Selecting the right patient is everything. Q: How to define CCR? @AndreaNecchi #gu26 #cancer #oncology #ASCO @oncoalert @ASCO @yekeduz_emre @CParkMD @OncBrothers @Larvol @nataliagandur @crisbergerot @ONCOassist @IMG_Oncologists @apolo_andrea

Perioperative MIBC is entering a new era. The question is no longer if. It is which regimen, for which patient. #gu26 #cancer #oncology #ASCO @oncoalert @ASCO @yekeduz_emre @CParkMD @OncBrothers @Larvol @nataliagandur @crisbergerot @ONCOassist @IMG_Oncologists

Muharrem Coşkunpınar: Expanding Perspectives in Metastatic Bladder and Kidney Cancer Care oncodaily.com/voices/muharre…

I am truly honored and delighted to have participated in the @myESMO Preceptorship on Metastatic Bladder and Kidney Cancer ✨ It was an inspiring experience to learn from world-leading experts in the field, gain insights into the latest advances, and —most importantly—have the opportunity to meet them in person, exchange ideas, and engage in meaningful scientific discussions 🧠 I would like to express my sincere gratitude to @myESMO for organizing such an outstanding educational program that broadens perspectives, strengthens multidisciplinary thinking, and fosters international collaboration 🤝💪🏻 @AlbigesL @tompowles1 @myESMO #oncology #bladder #kidney #cancer

In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: nej.md/4czl8sG Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nej.md/4twnv5T

7/ A cross-border collaboration. RECON Case Rounds—bringing together young oncologists from Pakistan 🇵🇰and Türkiye 🇹🇷 to discuss real-world cases online, with sessions endorsed by the Turkish Society of Medical Oncology.

Tıbbi Onkoloji Bilim Dalımız FDA Denetiminden Tam Not Aldı 🔗 medicine.ankara.edu.tr/2026/02/06/tib…

✨The ASCO Virtual Town Hall: From Mentorship to Manuscript was a thoughtful reminder that good science is built by people, not just projects. The sessions highlighted how mentorship, teamwork, and clear authorship practices help create trust, creativity, and meaningful academic impact. 🧠Open discussions on communication, shared goals, and common challenges—including those faced by trainees from LMICs—made the conversation especially relatable and practical. Many thanks to @ASCO , and all the speakers for fostering such an open, supportive, and inspiring space for learning and connection. #oncology #mentorship #LMIC #collaboration @NazliDizman @IshwariaMD @crisbergerot @thenasheffect @saadnasir01 @RyanNipp @matolani @OAlhalabiMD @Rubagumyaf @DrYukselUrun

Huge Congrats @yekeduz_emre @MikeSerzanMD @DrChoueiri and the whole team. 🧬Strong work clarifying the aggressive biology of NF2/merlin-loss RCC and why IO benefit may be limited. This is exactly why molecularly tailored strategies matter. @AACR @DanaFarber @OncoAlert @CCR_AACR @DanaFarber_GU doi.org/10.1158/1078-0…

Huge congrats to brilliant mentees @hatice_bolek @coskunyazgann and mente/mentor @yekeduz_emre Big thanks to @DrChoueiri @montypal @BradMcG04 and @DrRanaMcKay for their outstanding contributions, guidance, and support! 🔑IO rechallenge + VEGF TKI no survival gain in mRCC. @OncJournal @OncoAlert @Ankaratip1945 @AnkaraUni @IKCCorg @kidneycan @KidneyCancer @Uromigos doi.org/10.1093/oncolo…

Today, I had the opportunity to present our renal cell carcinoma case at Turkey–Pakistan Genitourinary Cancers Case Rounds webinar 👨‍💻 It was a highly valuable meeting where genitourinary cancer cases were discussed from all perspectives, with practice-oriented and up-to-date discussions 📚 Many thanks to the organizing committee @saadnasir01 @onurbas @DenizCanGuven1 for this educational and collaborative initiative, and special thanks to our mentor, @DrYukselUrun for his valuable insights and comments 🙏🏼🙏🏼

Bladder cancer: 614k new cases and 221k deaths (2022) ♂️3 in 4 in men. 🌍Highest rates in Southern Europe. 🚭Smoking still leading cause 🦠schistosomiasis in N Africa. @EUplatinum @Uroweb @WorldBladderCan @OncoAlert @Albert0Briganti doi.org/10.1016/j.euru…

So happy to have @DeryaTR_ as our keynote speaker at the our 11th annual meeting. AI in medicine brings hope, questions, and responsibility, all shared today. @AnkaraUni @OpenAI @Gemini #AI #research

Great pleasure to open our annual meeting with dear @curijoey Strong science, open questions, a look to the future of breast cancer care. @myESMO @Ankaratip1945 @AnkaraUni

Kicking off #OncologyHighlights2025 in Ankara with Prof. Giuseppe Curigliano (ESMO President) on the evolving ADC landscape in breast cancer—DESTINY-Breast11/DB05 insights, sequencing questions, and what’s next for better patient care. #BreastCancer @myESMO @ESOncology